Home

New Cancer Blood Test Technology Advances Accuracy and Tumor Diagnosis

OTraces is developing and preparing to commercialize in the U.S. and possibly certain markets in Asia patent-pending methodology that uses noise suppression to: 1) enhance cancer blood test accuracy to unprecedented levels and 2) to gain access to the diagnostic content of the tumor microenvironment (TME) —- two industry breakthroughs that can perhaps best be described and summarized by the following video that was recently presented by senior management at an oncology conference in New York.

Click here to view the Slide Show Presented at the New York Oncology Conference Sponsored by the National Foundation for Cancer Research

NEWS RELEASES:
-Presentation at the RESI / J.P. Morgan Healthcare 2018
-RESI 2018 Session Poster Presentation.
-Beyond Liquid Biopsy-OTraces White Paper

Contacts:

Company/Investor Inquiries:
Keith Lingenfelter
CEO
OTraces
phone: +01-301-529-3824
email: keith.lingenfelter@otraces.com

Contact-Media Inquiries:
Nancy Rose Senich
phone: +01-202-262-6996 cell/txt
email: nancy@rose4results.com